Research programme: neurotrauma therapeutics - InflamaCORE

Drug Profile

Research programme: neurotrauma therapeutics - InflamaCORE

Alternative Names: ICCN-100

Latest Information Update: 11 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator InflamaCORE
  • Class Antibodies; Monoclonal antibodies
  • Mechanism of Action Inflammasome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Brain injuries; Spinal cord injuries

Most Recent Events

  • 11 Aug 2016 Early research in Brain injuries in USA (unspecified route)
  • 11 Aug 2016 Early research in Spinal cord injuries in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top